Dr. Soni brings 20+ years of experience working with large and emerging pharmaceutical companies. He has led multidisciplinary teams across the entire drug development spectrum – from translational medicine to successful approval. As Head of Development at Amarin, Dr. Soni led the development of Amarin’s clinical trial and regulatory strategy for its natural product fish oil drug Vascepa. Dr. Soni will guide clinical and regulatory strategy for Cardax’s pharmaceutical platform, interact with the FDA, and advise the Company on a full range of development issues.
Previously, Dr. Soni served as the Chief Medical Officer of Albireo, a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases. Prior to Albireo, Dr. Soni served as Vice President, Global Medical Sciences at Alexion Pharmaceuticals where he advanced Kanuna (sebilipase alpha) for Lysosomal Acid Lipase Deficiency.
Dr. Soni was the former Senior Vice President and Head of Development for Amarin Corporation. As Head of Development at Amarin, Dr. Soni led the development of Amarin’s clinical trial and regulatory strategy for its natural product fish oil drug Vascepa, including its MARINE, ANCHOR, and REDUCE-IT clinical studies. Vascepa was recently approved by the FDA for reduction of triglycerides in adult patients with severe hypertriglyceridemia.